Compare Incyte Corporation (INCY) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs T Rowe Price Group Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while T Rowe Price Group Inc trades at $117.63 (market cap $25.14B). The key difference: Incyte Corporation and T Rowe Price Group Inc are close in size by market cap, and T Rowe Price Group Inc pays a 4.43% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TROW | |
|---|---|---|
Market Cap | $23.11B | $25.14B |
Sector | Health | Financials |
52-Week High | $118.52 | $120.16 |
52-Week Low | $67.38 | $86.19 |
Enterprise Value | $19.13B | $21.85B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
T. Rowe Price (TROW) trades at $116.345, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings that beat expectations, with revenue growth from $7.1B in 2024 to $7.3B in 2025 and a net income margin of 28.28%. Recent news highlights the launch of an active crypto ETF and AUM reaching $1.89 trillion in June 2026.
The outlook for TROW is mixed; valuation ratios like a P/E of 12.59 suggest potential undervaluation, but analyst consensus is cautious with a hold-heavy rating. Key risks include equity outflows and market volatility, while opportunities lie in diversified AUM growth and innovation. The stock's performance hinges on sustaining profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
